Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 221-111-2 | CAS number: 3006-86-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 20 December 2012 to 07 June 2013
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 013
- Report date:
- 2013
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.3700 (Prenatal Developmental Toxicity Study)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: Japanese Ministry of Agriculture, forestry abd Fisheries Testing guidelines for Toxicology Studies, 12 NohSan No 8147, (24 November 2000)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.31 (Prenatal Developmental Toxicity Study)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- Di-tert-butyl 3,3,5-trimethylcyclohexylidene diperoxide
- EC Number:
- 229-782-3
- EC Name:
- Di-tert-butyl 3,3,5-trimethylcyclohexylidene diperoxide
- Cas Number:
- 6731-36-8
- Molecular formula:
- C17H34O4
- IUPAC Name:
- 1,1-bis(tert-butylperoxy)-3,3,5-trimethylcyclohexane
- Test material form:
- other: clear, colourless liquid
- Details on test material:
- Identification: Di-tert-butyl 3,3,5-trimethylcyclohexylidene diperoxide (CAS# 6731-36-8)
Description: Clear colorless liquid
Batch: 0905137109
Label: Trigonox 29 0905137109 2kg
Purity: 93.4%
Date Received: 18 December 2012
Expiry Date: 01 June 2019
Storage Conditions: Stored frozen at approximately -20 °C; used/formulated at ambient temperature <30 °C
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Details on test animals or test system and environmental conditions:
- A total of one hundred and twenty time-mated female Sprague-Dawley Crl:CD (SD) IGS BR strain rats were obtained from Charles River (UK) Limited, Margate, Kent. Animals were delivered in two batches containing females prior to Day 3 of gestation. The day that positive evidence of mating was observed was designated Day 0 of gestation. On arrival the females weighed 212 to 292g.
The animals were housed individually in solid-floor polypropylene cages with stainless steel lids furnished with softwood flakes (Datesand Ltd., Cheshire, UK). The animals were allowed free access to food and water. A pelleted diet (Rodent 2018C Teklad Global Certified Diet, Harlan UK, Oxon, UK) was used. A certificate of analysis of the batch of diet used is given in Appendix 22. Mains drinking water was supplied from polycarbonate bottles attached to the cage. The diet and drinking water were considered not to contain any contaminant at a level that might have affected the purpose or integrity of the study. Environmental enrichment was provided in the form of wooden chew blocks and cardboard fun tunnels (Datesand Ltd., Cheshire, UK). There were no contaminants that might have affected the purpose or integrity of the study.
The animals were housed in a single air-conditioned room within the Harlan Laboratories Ltd., Shardlow, UK Barrier Maintained Rodent Facility. The rate of air exchange was at least fifteen air changes per hour and the low intensity fluorescent lighting was controlled to give twelve hours continuous light and twelve hours darkness. Environmental conditions were continuously monitored by a computerised system, and print-outs of hourly mean temperatures and humidity were included in the study records. The temperature and relative humidity controls were set to achieve target values of 21 ± 2 ºC and 55 ± 15% respectively. Occasional deviations from the humidity target were considered not to have affected the purpose or integrity of the study.
The animals were randomly allocated to treatment groups using a randomisation procedure based on stratified body weight to ensure similarity between the treatment groups. The animals were uniquely identified within the study by an ear punching system routinely used in these laboratories.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Remarks:
- dried
- Details on exposure:
- For the purpose of the study, the test item was prepared at the appropriate concentrations as a solution in Dried Corn Oil. The stability and homogeneity of the test item formulations were determined by Harlan Laboratories Ltd., Shardlow, UK Analytical Services. Results are given in Appendix 15 and show the formulations to be stable for four hours. Formulations were therefore prepared daily.
Samples were taken of each test item formulation and were analysed for concentration of Di-tert-butyl 3,3,5-trimethylcyclohexylidene diperoxide (CAS# 6731-36-8) at Harlan Analytical Laboratory, Shardlow. The results indicate that the prepared formulations were within ± 4% of the nominal concentration - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Summary
The concentration of Di-tert-butyl 3,3,5-trimethylcyclohexylidene diperoxide (CAS# 6731-36-8) in the test item formulations was determined by gas chromatography (GC) using an external standard technique.
Samples
The test item formulations were extracted with acetonitrile to give a final, theoretical test item concentration of approximately 0.2 mg/ml.
Standards
Standard solutions of test item were prepared in acetonitrile at a nominal concentration of 0.2 mg/ml.
Procedure
The standard and sample solutions were analysed by GC using the following conditions:
GC system :Agilent Technologies 5890, incorporating autosampler and workstation
Column :DB-5 (30 m x 0.53 mm id x 5 µm film)
Oven temperature program :initial 50 ºC for 0 mins
rate 10 ºC/min
temp 130 ºC for 0 mins
rate 50 ºC/min
final 260 ºC for 10 mins
Injection temperature :150 ºC
Flame ionisation detector temperature :250 ºC
Injection volume: 2 µL
Retention time :~ 6.5 mins
Homogeneity Determinations
The test item formulations were assessed visually.
Stability Determinations
The test item formulations were sampled and analysed initially and then after storage at ambient conditions for four hours.
Verification of Test Item Formulation Concentrations
The test item formulations were sampled and analysed on the day of preparation. - Details on mating procedure:
- Not described in this study
- Duration of treatment / exposure:
- 14 days (Between days 5 and 19 of gestation)
- Frequency of treatment:
- Daily
- Duration of test:
- 20 days
Doses / concentrationsopen allclose all
- Dose / conc.:
- 30 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 100 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 24 females
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- The animals were randomly allocated to treatment groups using a randomisation procedure based on stratified body weight to ensure similarity between the treatment groups. The animals were uniquely identified within the study by an ear punching system routinely used in these laboratories.
Justification
The rat was selected for this study as it is a readily available rodent species historically used in safety evaluation studies and is acceptable to appropriate regulatory authorities.
Examinations
- Maternal examinations:
- Clinical Observations
Following arrival, all animals were examined for overt signs of toxicity, ill-health or behavioural changes once daily during the gestation period. Additionally, during the dosing period, observations were recorded immediately before and soon after dosing and one hour post dosing. An additional observation was also performed five hours after dosing during the normal working week. All observations were recorded.
Body Weight
Individual body weights were recorded on Day 3 (before the start of treatment) and on Days 5, 6, 7, 8, 11, 14 and 17 of gestation. Body weights were also recorded for animals at terminal kill (Day 20).
Food Consumption
Food consumption was recorded for each individual animal at Day 3, 5, 8, 11, 14, 17 and 20 of gestation.
Water Consumption
Water intake was observed daily by visual inspection of the water bottles for any overt changes.
3.4.5 Post Mortem
All animals were killed by carbon dioxide asphyxiation followed by cervical dislocation.
All implantations and viable foetuses were numbered according to their intrauterine position as follows (as an example):
Left Horn Cervix Right Horn
L1 L2 L3 L4 L5 L6 L7 L8 R1 R2 R3 R4 R5 R6 R7 R8
V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 V15 V16
V = viable foetus
Organ Weights
The liver and kidneys were removed from all animals that were killed at the end of the study and were dissected free from fat and weighed before fixation.
Histopathology
The liver and kidneys were removed from all parental animals and preserved in buffered 10% formalin. The tissues from all control and 1000 mg/kg bw/day dose group animals were prepared as paraffin blocks, sectioned at a nominal thickness of 5 µm and stained with Haematoxylin and Eosin for subsequent microscopic examination.
Since there were indications of treatment-related liver changes, examination was subsequently extended to include similarly prepared sections of the liver from all animals from the low and intermediate groups. - Ovaries and uterine content:
- All animals were killed by carbon dioxide asphyxiation followed by cervical dislocation on Day 20 of gestation. All animals were subjected to a full external and internal examination and any macroscopic abnormalities were recorded. The ovaries and uteri of pregnant females were removed, examined and the following data recorded:
i) Number of corpora lutea
ii) Number, position and type of intrauterine implantation
iii) Foetal sex
iv) External foetal appearance
v) Foetal weight
vi) Placental weight
vii) Gravid uterus weight
The uteri of any apparently non-pregnant females were immersed in 0.5 % ammonium poly sulphide to reveal evidence of implantation.
Implantation types were divided into:
Early Death: No visible distinction between placental/decidual tissue and embryonic tissue
Late Death: Separate embryonic/foetal and placental tissue visible
Dead Foetus: A foetus that had died shortly before necropsy. These were included as late deaths for reporting purposes - Fetal examinations:
- The foetuses were killed by subcutaneous injection of sodium pentobarbitone. Foetuses from each litter were divided into two groups and examined for skeletal alterations and soft tissue alterations. Alternate foetuses were identified using an indelible marker and placed in Bouin’s fixative. Foetuses were transferred to 90% industrial methylated spirits (IMS) in distilled water and examined for visceral anomalies under a low power binocular microscope. The remaining foetuses were identified using colour coded wires and placed in 70% IMS in distilled water. The foetuses were eviscerated, processed and the skeletons stained with alizarin red. The foetuses were examined for skeletal development and anomalies. Following examination foetuses that were examined for skeletal development were placed in 100% glycerol.
- Statistics:
- The following parameters were analyzed statistically, where appropriate, using the test methods outlined below:
Female body weight change, food consumption and gravid uterus weight: Bartlett’s test for homogeneity of variance and one way analysis of variance, followed by Dunnett’s multiple comparison test or, if unequal variances were observed, on alternative multiple comparison test.
All caesarean necropsy parameters and foetal parameters: Kruskal-Wallis non-parametric analysis of variance; and a subsequent pairwise analysis of control values against treated values using the Mann-Whitney ‘U’ test, where significance was seen.
Foetal evaluation parameters, including skeletal or visceral findings: Kruskal-Wallis non-parametric analysis of variance and Mann-Whitney ‘U’ test.
Probability values (p) are presented as follows:
p<0.001 ***
p<0.01 **
p<0.05 *
p≥0.05 (not significant)
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- no effects observed
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Females from all treatment groups showed an increase in liver weight both absolute and relative to terminal body weight. Statistical significant was achieved in 100, 300 and 1000 mg/kg bw/day females (p<0.05 - 0.001).
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Twenty-one females treated with 1000 mg/kg bw/day, seventeen females treated with 300 mg/kg bw/day and three females treated with 100 mg/kg bw/day had an enlarged liver at necropsy. One of the females treated with 1000 mg/kg bw/day also had discolouration on the right lobe of the liver.
No such effects were detected in females treated with 30 mg/kg bw/day.
One female treated with 1000 mg/kg bw/day had a mass on the mammary gland. This was confirmed as a malignant tumour adenocarcinoma following histopathological examination. In isolation, this was considered not to be related to treatment. - Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Histopathological findings: neoplastic:
- effects observed, non-treatment-related
- Other effects:
- no effects observed
Maternal developmental toxicity
- Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- no effects observed
- Total litter losses by resorption:
- no effects observed
- Early or late resorptions:
- no effects observed
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- not examined
- Changes in number of pregnant:
- not examined
- Other effects:
- no effects observed
Effect levels (maternal animals)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- other: no adverse effects observed. Please refer to remarks
Maternal abnormalities
- Key result
- Abnormalities:
- no effects observed
Results (fetuses)
- Fetal body weight changes:
- no effects observed
- Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- no effects observed
- Changes in postnatal survival:
- not examined
- External malformations:
- no effects observed
- Skeletal malformations:
- no effects observed
- Visceral malformations:
- no effects observed
- Other effects:
- no effects observed
Effect levels (fetuses)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: There were no adverse effects observed.
Fetal abnormalities
- Key result
- Abnormalities:
- no effects observed
Overall developmental toxicity
- Key result
- Developmental effects observed:
- no
Any other information on results incl. tables
Mortality
There were no unscheduled deaths.
Clinical Observations
Females treated with 1000 and 300 mg/kg bw/day showed incidences of increased salivation from Day 6 and 14, respectively. No such effects were detected in females treated with 100 or 30 mg/kg bw/day.
Body Weight
No adverse effect on body weight development was detected. Statistical analysis did not reveal any significant differences.
Food Consumption
No adverse effect on dietary intake was detected.
Females treated with 1000 mg/kg bw/day showed a statistically significant reduction (p<0.001) in food consumption between Days 5 and 8. Recovery was evident thereafter, with values for these treated females actually being higher than control values therefore in isolation the intergroup difference was considered not to be of toxicological significance.
Water Consumption
Daily visual inspection of water bottles did not reveal any overt intergroup differences.
No adverse effect on water consumption was detected.
Post Mortem Studies
Twenty-one females treated with 1000 mg/kg bw/day, seventeen females treated with 300 mg/kg bw/day and three females treated with 100 mg/kg bw/day had an enlarged liver at necropsy. One of the females treated with 1000 mg/kg bw/day also had discolouration on the right lobe of the liver.
No such effects were detected in females treated with 30 mg/kg bw/day.
One female treated with 1000 mg/kg bw/day had a mass on the mammary gland. This was confirmed as a malignant tumour adenocarcinoma following histopathological examination. In isolation, this was considered not to be related to treatment.
Organ Weights
Females from all treatment groups showed an increase in liver weight both absolute and relative to terminal body weight. Statistical significant was achieved in 100, 300 and 1000 mg/kg bw/day females (p<0.05 - 0.001).
Histopathology
Liver:Minimal to moderate centrilobular hypertrophy of hepatocytes was evident in females from all treatment groups.
Hepatocyte enlargement is commonly observed in the rodent liver following the administration of xenobiotics and in the absence of associated inflammatory or degenerative changes is generally considered to be adaptive in nature and does not represent an adverse health effect.
Litter Responses
Litter Data and Litter Placental and Foetal Weights
There was no adverse effect on in-utero offspring survival, as assessed by the mean numbers of early or late resorptions, live litter size and post-implantation losses. There were also no adverse effects on pre-implantation losses or sex ratio.
Females treated with 300 mg/kg bw/day showed an increase in male and female foetal weights. Females treated with 30 mg/kg bw/day also showed an increase in male foetal weights. An increase in body weight is considered not to be of toxicological significance.
Foetal Examination
For all dose groups, there were no significant treatment-related trends in the proportion of foetuses (or litters) with evidence of visceral or skeletal anomalies. The type of visceral and skeletal anomalies were those commonly observed for this type of study.
Females treated with 300 mg/kg bw/day showed a statistically significant increase in the number of foetuses showing greater than six ossified metacarpals. Subsequently these females also showed a statistically significant reduction in the number of foetuses showing six ossified metacarpals. The standard number of ossified metacarpals in Day 20 foetuses is greater than six. Therefore the intergroup differences indicate a higher number of foetuses showing a normal number of ossified metacarpals compared to controls and in the absence of a true dose related response as such, are considered of no toxicological importance.
Females treated with 1000 mg/kg/day showed a statistically significant increase in the percentage of foetuses showing one lumbar vertebral centre semi-bipartite. Females treated with 100 mg/kg bw/day showed a statistically significant increase in the percentage of foetuses showing one thoracic vertebral centre bipartite. The observation of one variant at a higher incidence compared with controls is not significant when evaluated in isolation. The number of parameters evaluated makes it highly likely that one finding will be seen at a higher level in dosed groups compared with controls. A true developmental effect is only seen when a number of variants or a syndrome of variance is observed. Therefore these intergroup differences are of no biological significance.
Applicant's summary and conclusion
- Conclusions:
- The oral administration of Di-tert-butyl 3,3,5-trimethylcyclohexylidene diperoxide (CAS# 6731-36-8) to pregnant rats by oral gavage during organogenesis at dose levels of 30, 100, 300 and 1000 mg/kg/day resulted in adaptive liver effects in parental females. The ‘No Observed Adverse Effect Level’ (NOAEL) was therefore, considered to be 1000 mg/kg/day.
No toxicological significant changes were detected in the offspring parameters measured. The ‘No Observed Effect Level’ (NOEL) for developmental toxicity was therefore considered to be 1000 mg/kg/day. - Executive summary:
The read across study was performed to investigate the effects of the test item on embryonic and foetal development following repeated administration by gavage to the pregnant female during the period of organogenesis.
The study was designed to comply with the following guidelines:
* US EPA Health Effects Test Guidelines OPPTS 870.3700, 'Prenatal Developmental Toxicity Stidy' (August 1998)
* Japanese Ministry of Agriculture, Forestry and Fisheries Testing guidelines for Toxicology Studies, 12 NohSan No 8147, (24 November 2000)
* OECD Guidelines for Testing of Chemicals, No 414, 'Prenatal Developmental Toxicity Study' (adopted 22 January 2001)
* Commission Regulation (ES) No 440/2008 of 30 May 2008 test methods pursuant to Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)
Methods
The test item was administered by gavage to four groups each of twenty-four time mated Sprague-Dawley Crl:CD®(SD) IGS BR strain rats, between Days 5 and 19 of gestation inclusive at dose levels 30, 100, 300 and 1000 mg/kg bw/day. A further group of twenty-four time mated females was exposed to the vehicle only (Dried Corn oil) to serve as a control.
Clinical signs, body weight change, food and water consumptions were monitored during the study. Liver and kidney weights were recorded for all females at termination and histopathological evaluation of the liver and kidneys was performed.
All females were terminated on Day 20 of gestation and subjected to gross necropsy including examination of the uterine contents. The number of corpora lutea, number, position and type of implantation, placental weights, foetal weight, sex and external and internal macroscopic appearance were recorded. Half of each litter were preserved in 70% Industrial Methylated Spirit (IMS) in distilled water and then following examination for skeletal development transferred into 100% glycerol. The remaining half were preserved in Bouin’s solution and transferred to 90% IMS in distilled water and examined viscerally.
Results
Mortality
There were no unscheduled deaths.
Clinical Observations
Females treated with 1000 and 300 mg/kg bw/day showed incidences of increased salivation. No such effects were detected in females treated with 100 or 30 mg/kg bw/day.
Body Weight
No treatment related effects in body weight development were detected.
Food Consumption
No toxicologically significant effects were detected in food consumption.
Water Consumption
No adverse effect on water consumption was detected.
Post Mortem Studies
Females treated with 1000, 300 and 100 mg/kg bw/day had an enlarged liver at necropsy. One female treated with 1000 mg/kg bw/day also had discolouration on the right lobe of the liver. No such effects were detected in females treated with 30 mg/kg bw/day.
Organ Weights
Females from all treatment groups showed an increase in liver weight both absolute and relative to terminal body weight.
Histopathology
The following treatment related microscopic effects were detected:
Liver:Minimal to moderate centrilobular hypertrophy of hepatocytes was evident in females from all treatment groups.
Litter Data and Litter Placental and Foetal Weights
No treatment-related effects were detected in the uterine parameters examined, in foetal viability or in growth and development.
Foetal Examination
No treatment-related effects were detected on skeletal development or in the type and incidence of skeletal or visceral findings.
Conclusion
The oral administration of Di-tert-butyl 3,3,5-trimethylcyclohexylidene diperoxide (CAS# 6731-36-8) to pregnant rats by oral gavage during organogenesis at dose levels of 30, 100, 300 and 1000 mg/kg/day resulted in adaptive liver effects in parental females. The ‘No Observed Adverse Effect Level’ (NOAEL) was therefore, considered to be 1000 mg/kg/day.
No toxicological significant changes were detected in the offspring parameters measured. The ‘No Observed Effect Level’ (NOEL) for developmental toxicity was therefore considered to be 1000 mg/kg/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.